Invivyd
Invivyd's revenue rose 110.5% to $53 million in fiscal 2025. Its operating margin was −104.0%, up from −696.8% a year earlier. Free cash flow was −$58 million. The diluted share count rose 45.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Invivyd does
Invivyd is a biopharmaceutical company that develops monoclonal antibody medicines, which are lab-made proteins, to prevent and treat serious viral infections. It started with COVID-19 and says it aims to extend into other diseases such as respiratory syncytial virus and measles.
Its only authorized product is Pemgarda, which the FDA authorized for emergency use on March 22, 2024. It is given by intravenous infusion to prevent COVID-19 in adults and adolescents aged 12 and older who are moderately to severely immune compromised and unlikely to respond well to vaccination. It is an emergency use authorization rather than a full approval, and it lasts only while the COVID-19 emergency declaration for drugs stays in place and while the circulating variants are ones it is expected to work against.
Invivyd earns money by selling Pemgarda. It is also developing other antibody candidates, including VYD2311.
Its biggest risks, as it describes them
- Its financial condition raises substantial doubt about whether it can continue as a going concern.
- It depends heavily on Pemgarda, its only authorized product, which has only emergency use authorization.
- New COVID-19 variants could reduce how well its antibodies work.
- It has little experience selling products and has lost money since it began.
- Its loan agreement has terms that, if broken, could lead to a default.
Income statement
Invivyd lost money in fiscal 2025: a net loss of $52 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 542 | 92 | 201 | 69 | 227 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 9.9x | 15.1x | 4.5x | 1.6x | 7.2x |
| Quick ratio | 9.9x | 15.1x | 4.5x | 1.2x | 7.1x |
Cash flow
Projections
Project Invivyd's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Invivyd shares on the open market, and 4 insiders sold $341,120, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Jill AndersenChief Legal Officer, Secretary | Sold plan | 30,706 | $0.84 | $25,793 | Form 4 |
| Aug 18, 2026 | William E. DukeChief Financial Officer | Sold plan | 18,425 | $0.84 | $15,477 | Form 4 |
| Aug 18, 2026 | Robert D. Allen IIIChief Scientific Officer | Sold plan | 17,043 | $0.84 | $14,316 | Form 4 |
| Aug 17, 2026 | Jill AndersenChief Legal Officer, Secretary | Sold plan | 37,256 | $0.72 | $26,824 | Form 4 |
| Aug 17, 2026 | William E. DukeChief Financial Officer | Sold plan | 22,355 | $0.72 | $16,096 | Form 4 |
| Aug 17, 2026 | Robert D. Allen IIIChief Scientific Officer | Sold plan | 20,679 | $0.72 | $14,889 | Form 4 |
| Feb 18, 2026 | Jill AndersenChief Legal Officer, Secretary | Sold plan | 34,939 | $1.58 | $55,204 | Form 4 |
| Feb 18, 2026 | Timothy Edward LeeChief Commercial Officer | Sold plan | 20,964 | $1.58 | $33,123 | Form 4 |
| Feb 18, 2026 | Robert D. Allen IIIChief Scientific Officer | Sold plan | 19,392 | $1.58 | $30,639 | Form 4 |
| Feb 17, 2026 | Jill AndersenChief Legal Officer, Secretary | Sold plan | 32,771 | $1.54 | $50,467 | Form 4 |
| Feb 17, 2026 | Timothy Edward LeeChief Commercial Officer | Sold plan | 19,663 | $1.54 | $30,281 | Form 4 |
| Feb 17, 2026 | Robert D. Allen IIIChief Scientific Officer | Sold plan | 18,189 | $1.54 | $28,011 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | 1.4% |
| Altman Z'' | −8.05 | −28.78 | −0.36 |
| Accruals ratio | −8.3% | 0.3% | 2.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Pass | Pass |
| F-score | — | — | — |
Compare
Put Invivyd side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Invivyd | FY25 | 110.5% | −104.0% | −109.1% | — | — | — | |
| Q32 Bio | FY25 | — | 31.4% | −62.4% | — | −2.8x | 3 | Compare |
| Protalix BioTherapeutics | FY25 | −1.2% | −10.4% | −25.8% | — | — | — | Compare |
| Gossamer Bio | FY25 | −57.7% | −352.2% | −353.5% | — | — | 0 | Compare |
| Champions Oncology | FY26 | 4.4% | −1.9% | −8.5% | — | — | — | Compare |
5 years of figures
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | 0 | 25 | 53 |
| Revenue growth | — | — | — | — | 110.5% |
| Gross profit | — | — | — | — | — |
| Research and development | 183 | 179 | 159 | 137 | 38 |
| Operating income | −227 | −248 | −213 | −177 | −56 |
| Net income | −227 | −241 | −199 | −170 | −52 |
| Diluted EPS (US$) | −5.32 | −2.23 | −1.81 | −1.43 | −0.30 |
| Diluted shares (millions) | 43 | 108 | 110 | 119 | 172 |
| Cash flow | |||||
| Cash from operations | −185 | −220 | −173 | −170 | −58 |
| Capital expenditure | 0 | 2 | 1 | 0 | 0 |
| Free cash flow | −185 | −222 | −174 | −171 | −58 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 18 | 22 | 19 | 20 | 12 |
| Balance sheet at fiscal year end | |||||
| Cash and short-term investments | 542 | 92 | 201 | 69 | 227 |
| Debt incl. finance leases | — | — | — | — | — |
| Total assets | 620 | 383 | 229 | 130 | 277 |
| Total liabilities | 62 | 27 | 52 | 62 | 35 |
| Shareholders' equity | 558 | 356 | 178 | 68 | 242 |
| Margins and ratios | |||||
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | −696.8% | −104.0% |
| Net margin | — | — | — | −669.4% | −98.2% |
| Free cash flow margin | — | — | — | −672.2% | −109.1% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | 1.4% |
| Return on capital | — | — | — | — | — |
| Return on equity | — | −52.8% | −74.5% | −138.7% | −34.0% |
| Return on assets | — | −48.1% | −64.9% | −94.8% | −25.8% |
| Net debt to EBITDA | — | — | — | — | — |